{"id":"NCT01312766","sponsor":"IBSA Institut Biochimique SA","briefTitle":"Safety and Efficacy Study in in Vitro Fertilisation (IVF) Patients","officialTitle":"Safety and Efficacy Study Comparing a New hMG Formulation (hMG-IBSA) to a Reference Product (MenopurÂ®) in Patients Undergoing Ovarian Stimulation for in Vitro Fertilisation (IVF)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02","primaryCompletion":"2013-04","completion":"2013-12","firstPosted":"2011-03-11","resultsPosted":"2014-08-15","lastUpdate":"2016-07-22"},"enrollment":270,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Infertility"],"interventions":[{"type":"DRUG","name":"Menotropins","otherNames":[]},{"type":"DRUG","name":"Menotropins","otherNames":[]}],"arms":[{"label":"hMG-IBSA","type":"EXPERIMENTAL"},{"label":"Menopur","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the non-inferiority study is to evaluate the clinical efficacy and the safety of two different subcutaneous hMG preparations when administered to patients undergoing controlled ovarian stimulation for IVF.","primaryOutcome":{"measure":"Total Number of Oocytes Retrieved","timeFrame":"up to 24 days after treatment start","effectByArm":[{"arm":"hMG-IBSA","deltaMin":11.6,"sd":6.6},{"arm":"Menopur","deltaMin":9.7,"sd":5.9}],"pValues":[{"comp":"OG000 vs OG001","p":"0.012"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":16},"locations":{"siteCount":6,"countries":["Denmark","France","Hungary","Switzerland","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":135},"commonTop":["Headache","Abdominal distension","fatigue","Abdominal pain upper","Hot flushes"]}}